Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes
Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE. In...
Saved in:
| Published in | BMC medicine Vol. 23; no. 1; pp. 8 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
06.01.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.
In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death.
Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026).
SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. |
|---|---|
| AbstractList | Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.
In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death.
Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026).
SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. Background Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE. Methods In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-[beta]2 glycoprotein I antibodies (a[beta]2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death. Results Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), a[beta]2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026). Conclusions SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. Keywords: Systemic lupus erythematosus (SLE), Antiphospholipid syndrome (APS), Antiphospholipid antibodies (aPLs), Atherosclerotic cardiovascular disease (ASCVD), Aspirin BackgroundPatients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.MethodsIn total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death.ResultsAmong the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00–12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25–3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03–3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23–8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25–0.93, P = 0.026).ConclusionsSLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.BACKGROUNDPatients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death.METHODSIn total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death.Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026).RESULTSAmong the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026).SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD.CONCLUSIONSSLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-[beta]2 glycoprotein I antibodies (a[beta]2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death. Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), a[beta]2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00-12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25-3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03-3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23-8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25-0.93, P = 0.026). SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. Abstract Background Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE. Methods In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I antibodies (aβ2GPI) IgG/IgM, and lupus anticoagulant (LA), were measured in each center. Future ASCVD events were defined as new-onset myocardial infarction, stroke, artery revascularization, or cardiovascular death. Results Among the 1573 SLE patients, 525 (33.4%) had positive aPLs. LA had the highest prevalence (324 [20.6%]), followed by aCL IgG (249 [15.8%]), aβ2GPI IgG (199 [12.7%]). 116 (7.37%) patients developed ASCVD during the mean follow-up of 4.51 ± 2.32 years and 92 patients were aPLs positive. In univariate Cox regression analysis, both aPLs (HR = 7.81, 95% CI 5.00–12.24, p < 0.001) and traditional risk factors of cardiovascular disease were associated with future ASCVD events. In multiple Cox regression analysis, aCL IgG (HR = 1.95, 95% CI 1.25–3.00, p = 0.003), aCL IgM (HR = 1.83, 95% CI 1.03–3.20, p = 0.039), and LA (HR = 5.13, 95% CI 3.23–8.20, p < 0.001) positivity remained associated with ASCVD; traditional risk factors for ASCVD, including smoking, gender, age and hypertension, also play an independent role in SLE patients. More importantly, Aspirin can reduce ASCVD risk in SLE patients with positive aPLs (HR = 0.57 95% CI, 0.25–0.93, P = 0.026). Conclusions SLE patients with positive aPLs, especially positive aCL IgG/IgM and LA, warrant more care and surveillance of future ASCVD events during follow-up. Aspirin may have a protective effect on future ASCVD. |
| ArticleNumber | 8 |
| Audience | Academic |
| Author | Huang, Can Li, Mengtao Wei, Wei Wu, Lijun Ding, Yufang Zhao, Cheng Lin, Shudian Tian, Xinping Chen, Zhen Yang, Min Zeng, Xiaofeng Wang, Qian Zhao, Jiuliang |
| Author_xml | – sequence: 1 givenname: Can surname: Huang fullname: Huang, Can – sequence: 2 givenname: Yufang surname: Ding fullname: Ding, Yufang – sequence: 3 givenname: Zhen surname: Chen fullname: Chen, Zhen – sequence: 4 givenname: Lijun surname: Wu fullname: Wu, Lijun – sequence: 5 givenname: Wei surname: Wei fullname: Wei, Wei – sequence: 6 givenname: Cheng surname: Zhao fullname: Zhao, Cheng – sequence: 7 givenname: Min surname: Yang fullname: Yang, Min – sequence: 8 givenname: Shudian surname: Lin fullname: Lin, Shudian – sequence: 9 givenname: Qian surname: Wang fullname: Wang, Qian – sequence: 10 givenname: Xinping surname: Tian fullname: Tian, Xinping – sequence: 11 givenname: Jiuliang surname: Zhao fullname: Zhao, Jiuliang – sequence: 12 givenname: Mengtao surname: Li fullname: Li, Mengtao – sequence: 13 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39757171$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1q3DAQhU1JaX7aF-hFERRKeuHUki3L7k1ZQtMuBAptKLkTY2mcVfBaG0kO7PP0RTubTdpsKMXYkkffObZG5zDbG_2IWfaaFyecN_WHyEXL67wQVV6UTVXm7bPsgKuK56rgcu_RfD87jPG6KIRUqnqR7ZetkoorfpD9OpvSFJBBWmDw0Qz0TM4wA8E6fwvRTAMEZl1EiMjcyOI6JlwSMkyrKTIMa5IuIflIbx1BlvmRnf64mH1nx5eXP-fz-fuPjBiGfY8mMd-THU0DjonBmNxq4SPdg1s5e1fovHUYmYs-rVcYX2bPexgivrofj7KLs88Xp1_z829f5qez89zIVqa84wbLuu0AVdNIYXooOmkrUxhp67bqbVGXipZsJwxWQvRcAq8AjECEEsujbL61tR6u9Sq4JYS19uD0XcGHKw2BejOgbktoQJRFJ1BWpq-Bq7LuG1lXRWNls_H6tPVaTd0SraGtBhh2THdXRrfQV_5Wc64KIVRDDsf3DsHfTBiTXrpocBhgRD9FXXLJG1XXvCb07RP02k9hpFZtKFG3FAP1l7oC2oEbe08fNhtTPWuEqKpScEnUyT8ouuzmzCl_vaP6juDdI8ECYUiL6IcpOT_GXfDN45b86cVDFglotoChIMaAvTYuwcaHfsENmhd6E3u9jb2m2Ou72NNpHGXiifTB_T-i3xCIBlI |
| CitedBy_id | crossref_primary_10_1016_j_ejrad_2025_112037 |
| Cites_doi | 10.1093/rheumatology/kep062 10.1093/rheumatology/kes388 10.1016/S1474-4422(09)70239-X 10.1001/jamanetworkopen.2023.6530 10.2478/rir-2021-0001 10.1155/2018/3424136 10.1002/acr.21664 10.1136/annrheumdis-2019-215213 10.1002/art.24232 10.1016/j.mayocp.2019.01.044 10.2478/rir-2022-0033 10.1007/s10067-022-06056-8 10.3390/biomedicines11102814 10.1016/j.rdc.2014.04.003 10.1016/j.autrev.2013.10.014 10.1016/0002-9343(92)90578-Y 10.1016/j.semarthrit.2019.04.009 10.1111/j.1538-7836.2006.01753.x 10.1016/j.intimp.2021.107466 10.1042/CS20230499 10.3389/fimmu.2021.648881 10.1111/joim.13409 10.1111/jth.15047 10.1177/0961203315627199 10.1093/rheumatology/kep102 10.1111/jth.14633 10.1093/rheumatology/kez516 10.3389/fimmu.2019.00941 10.1136/annrheumdis-2013-205171 10.1016/j.jacc.2017.02.058 10.1161/01.STR.0000254476.05620.14 10.1093/eurheartj/ehae208 10.7150/ijbs.93544 10.1002/acr.20648 10.1177/0961203316637431 10.1016/j.cpcardiol.2023.101999 10.1016/S0140-6736(22)01349-6 10.1186/ar3473 10.1093/rheumatology/ker339 10.3899/jrheum.081194 10.1177/0961203317693096 10.1007/s10067-017-3927-8 10.5152/eurjrheum.2015.0085 10.1016/j.autrev.2023.103374 10.1136/annrheumdis-2020-218272 10.1016/j.atherosclerosis.2018.09.010 10.1161/CIRCULATIONAHA.117.027272 10.1093/rheumatology/keh384 10.1002/art.34473 10.1007/s00281-022-00916-w 10.1002/art.1780400928 10.1136/annrheumdis-2018-214819 10.1016/j.semarthrit.2012.12.002 10.1002/acr.20122 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-024-03843-9 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_93a8a230b2e54cf6a1736f856408d58e PMC11702278 A822443215 39757171 10_1186_s12916_024_03843_9 |
| Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | China Germany |
| GeographicLocations_xml | – name: China – name: Germany |
| GrantInformation_xml | – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-A-008, PUMCH-A-A038 – fundername: Beijing Municipal Natural Science Foundation grantid: No. Z 201100005520022,23, 25-27 – fundername: Chinese National Key Technology R&D Program, Ministry of Science and Technology grantid: 2021YFC2501300 – fundername: CAMS Innovation Fund for Medical Sciences (CIFMS) grantid: 2021-I2M-1-005 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PUEGO PMFND 3V. 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c595t-b1ce369bae78852cfa0b5d4c0c5d694fd0637788db2ce422f15a14aac2eea3e3 |
| IEDL.DBID | M48 |
| ISSN | 1741-7015 |
| IngestDate | Wed Aug 27 01:22:43 EDT 2025 Thu Aug 21 18:34:50 EDT 2025 Thu Jul 10 19:58:06 EDT 2025 Fri Jul 25 22:45:12 EDT 2025 Tue Jun 17 21:59:35 EDT 2025 Tue Jun 10 20:53:52 EDT 2025 Thu May 22 21:23:31 EDT 2025 Thu Aug 28 04:45:56 EDT 2025 Tue Jul 01 02:51:43 EDT 2025 Thu Apr 24 23:02:06 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antiphospholipid syndrome (APS) Aspirin Antiphospholipid antibodies (aPLs) Systemic lupus erythematosus (SLE) Atherosclerotic cardiovascular disease (ASCVD) |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c595t-b1ce369bae78852cfa0b5d4c0c5d694fd0637788db2ce422f15a14aac2eea3e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12916-024-03843-9 |
| PMID | 39757171 |
| PQID | 3152697417 |
| PQPubID | 42775 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_93a8a230b2e54cf6a1736f856408d58e pubmedcentral_primary_oai_pubmedcentral_nih_gov_11702278 proquest_miscellaneous_3151876616 proquest_journals_3152697417 gale_infotracmisc_A822443215 gale_infotracacademiconefile_A822443215 gale_healthsolutions_A822443215 pubmed_primary_39757171 crossref_citationtrail_10_1186_s12916_024_03843_9 crossref_primary_10_1186_s12916_024_03843_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-06 |
| PublicationDateYYYYMMDD | 2025-01-06 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medicine |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | W Chayoua (3843_CR37) 2020; 18 M Petri (3843_CR12) 2012; 64 M Chen (3843_CR52) 2024; 20 MB Urowitz (3843_CR45) 2010; 62 JS Knight (3843_CR7) 2022; 44 A Floris (3843_CR51) 2018; 2018 M Taraborelli (3843_CR21) 2017; 26 C Hu (3843_CR16) 2021; 12 J Mikdashi (3843_CR43) 2007; 38 GJ Pons-Estel (3843_CR46) 2009; 48 MG Tektonidou (3843_CR50) 2009; 61 3843_CR22 3843_CR27 F Ceccarelli (3843_CR32) 2023; 22 F Conti (3843_CR30) 2016; 25 C Huang (3843_CR10) 2022; 3 MND Di Minno (3843_CR48) 2018; 278 A Djokovic (3843_CR36) 2022; 41 MC Hochberg (3843_CR11) 1997; 40 IN Bruce (3843_CR20) 2015; 74 SR Schoenfeld (3843_CR39) 2013; 43 RT Urbanus (3843_CR34) 2009; 8 MG Tektonidou (3843_CR18) 2019; 78 L Arnaud (3843_CR49) 2014; 13 Z Touma (3843_CR42) 2012; 51 LF Pinto-Peñaranda (3843_CR24) 2018; 37 Y Zuo (3843_CR29) 2023; 6 A Fanouriakis (3843_CR1) 2021; 80 Y Zhao (3843_CR55) 2023; 137 JA de Lemos (3843_CR4) 2017; 135 S Sciascia (3843_CR19) 2013; 52 SA Chambers (3843_CR2) 2009; 48 MT Corban (3843_CR33) 2017; 69 G Katz (3843_CR25) 2019; 94 KMJ Devreese (3843_CR15) 2020; 18 M Nikpour (3843_CR41) 2011; 13 P Karakasis (3843_CR44) 2023; 48 SM Nidorf (3843_CR54) 2024; 45 T Kolitz (3843_CR8) 2019; 10 SG Deftereos (3843_CR53) 2022; 145 M Aringer (3843_CR13) 2019; 78 M Li (3843_CR9) 2021; 2 E Svenungsson (3843_CR35) 2022; 291 S Miyakis (3843_CR17) 2006; 4 A Danowski (3843_CR38) 2009; 36 J Mikdashi (3843_CR23) 2004; 43 M McMahon (3843_CR28) 2014; 40 M Radin (3843_CR47) 2019; 49 X Lu (3843_CR26) 2021; 94 BH Hahn (3843_CR14) 2012; 64 O Ünlü (3843_CR31) 2016; 3 N Conrad (3843_CR5) 2022; 400 MB Urowitz (3843_CR3) 2012; 64 M Petri (3843_CR40) 1992; 93 M Taraborelli (3843_CR6) 2016; 25 |
| References_xml | – volume: 48 start-page: 673 issue: 6 year: 2009 ident: 3843_CR2 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kep062 – volume: 52 start-page: 1397 issue: 8 year: 2013 ident: 3843_CR19 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kes388 – volume: 8 start-page: 998 issue: 11 year: 2009 ident: 3843_CR34 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70239-X – volume: 6 start-page: e236530 issue: 4 year: 2023 ident: 3843_CR29 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2023.6530 – volume: 2 start-page: 43 issue: 1 year: 2021 ident: 3843_CR9 publication-title: Rheumatol Immunol Res doi: 10.2478/rir-2021-0001 – volume: 2018 start-page: 3424136 year: 2018 ident: 3843_CR51 publication-title: Mediators Inflamm doi: 10.1155/2018/3424136 – volume: 64 start-page: 797 issue: 6 year: 2012 ident: 3843_CR14 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.21664 – volume: 78 start-page: 1296 issue: 10 year: 2019 ident: 3843_CR18 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-215213 – volume: 61 start-page: 29 issue: 1 year: 2009 ident: 3843_CR50 publication-title: Arthritis Rheum doi: 10.1002/art.24232 – volume: 94 start-page: 143C6 issue: 8 year: 2019 ident: 3843_CR25 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2019.01.044 – volume: 3 start-page: 184 issue: 4 year: 2022 ident: 3843_CR10 publication-title: Rheumatol Immunol Res doi: 10.2478/rir-2022-0033 – volume: 41 start-page: 1447 issue: 5 year: 2022 ident: 3843_CR36 publication-title: Clin Rheumatol doi: 10.1007/s10067-022-06056-8 – ident: 3843_CR27 doi: 10.3390/biomedicines11102814 – volume: 40 start-page: 475 issue: 3 year: 2014 ident: 3843_CR28 publication-title: Rheum Dis Clin North Am. doi: 10.1016/j.rdc.2014.04.003 – volume: 13 start-page: 281 issue: 3 year: 2014 ident: 3843_CR49 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2013.10.014 – volume: 93 start-page: 513 issue: 5 year: 1992 ident: 3843_CR40 publication-title: Am J Med doi: 10.1016/0002-9343(92)90578-Y – volume: 49 start-page: 464 issue: 3 year: 2019 ident: 3843_CR47 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2019.04.009 – volume: 4 start-page: 295 issue: 2 year: 2006 ident: 3843_CR17 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 94 start-page: 107466 year: 2021 ident: 3843_CR26 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2021.107466 – volume: 137 start-page: 1533 issue: 19 year: 2023 ident: 3843_CR55 publication-title: Clin Sci (Lond) doi: 10.1042/CS20230499 – volume: 12 start-page: 648881 year: 2021 ident: 3843_CR16 publication-title: Front Immunol doi: 10.3389/fimmu.2021.648881 – volume: 291 start-page: 327 issue: 3 year: 2022 ident: 3843_CR35 publication-title: J Intern Med doi: 10.1111/joim.13409 – volume: 18 start-page: 2828 issue: 11 year: 2020 ident: 3843_CR15 publication-title: J Thromb Haemost doi: 10.1111/jth.15047 – volume: 25 start-page: 719 issue: 7 year: 2016 ident: 3843_CR30 publication-title: Lupus doi: 10.1177/0961203315627199 – volume: 48 start-page: 817 issue: 7 year: 2009 ident: 3843_CR46 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kep102 – volume: 18 start-page: 169 issue: 1 year: 2020 ident: 3843_CR37 publication-title: J Thromb Haemost doi: 10.1111/jth.14633 – ident: 3843_CR22 doi: 10.1093/rheumatology/kez516 – volume: 10 start-page: 941 year: 2019 ident: 3843_CR8 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00941 – volume: 74 start-page: 1706 issue: 9 year: 2015 ident: 3843_CR20 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205171 – volume: 69 start-page: 2317 issue: 18 year: 2017 ident: 3843_CR33 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.02.058 – volume: 38 start-page: 281 issue: 2 year: 2007 ident: 3843_CR43 publication-title: Stroke doi: 10.1161/01.STR.0000254476.05620.14 – volume: 45 start-page: 1596 issue: 18 year: 2024 ident: 3843_CR54 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehae208 – volume: 20 start-page: 2092 issue: 6 year: 2024 ident: 3843_CR52 publication-title: Int J Biol Sci doi: 10.7150/ijbs.93544 – volume: 64 start-page: 132 issue: 1 year: 2012 ident: 3843_CR3 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.20648 – volume: 25 start-page: 1365 issue: 12 year: 2016 ident: 3843_CR6 publication-title: Lupus doi: 10.1177/0961203316637431 – volume: 48 start-page: 101999 issue: 12 year: 2023 ident: 3843_CR44 publication-title: Curr Probl Cardiol doi: 10.1016/j.cpcardiol.2023.101999 – volume: 400 start-page: 733 issue: 10354 year: 2022 ident: 3843_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(22)01349-6 – volume: 13 start-page: R156 issue: 5 year: 2011 ident: 3843_CR41 publication-title: Arthritis Res Ther doi: 10.1186/ar3473 – volume: 51 start-page: 528 issue: 3 year: 2012 ident: 3843_CR42 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ker339 – volume: 36 start-page: 1195 issue: 6 year: 2009 ident: 3843_CR38 publication-title: J Rheumatol doi: 10.3899/jrheum.081194 – volume: 26 start-page: 1197 issue: 11 year: 2017 ident: 3843_CR21 publication-title: Lupus doi: 10.1177/0961203317693096 – volume: 37 start-page: 949 issue: 4 year: 2018 ident: 3843_CR24 publication-title: Clin Rheumatol doi: 10.1007/s10067-017-3927-8 – volume: 3 start-page: 75 issue: 2 year: 2016 ident: 3843_CR31 publication-title: Eur J Rheumatol doi: 10.5152/eurjrheum.2015.0085 – volume: 22 start-page: 103374 issue: 8 year: 2023 ident: 3843_CR32 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2023.103374 – volume: 80 start-page: 14 issue: 1 year: 2021 ident: 3843_CR1 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-218272 – volume: 278 start-page: 60 year: 2018 ident: 3843_CR48 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.09.010 – volume: 135 start-page: 2119 issue: 22 year: 2017 ident: 3843_CR4 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.117.027272 – volume: 43 start-page: 1555 issue: 12 year: 2004 ident: 3843_CR23 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keh384 – volume: 64 start-page: 2677 issue: 8 year: 2012 ident: 3843_CR12 publication-title: Arthritis Rheum doi: 10.1002/art.34473 – volume: 44 start-page: 347 issue: 3 year: 2022 ident: 3843_CR7 publication-title: Semin Immunopathol doi: 10.1007/s00281-022-00916-w – volume: 40 start-page: 1725 issue: 9 year: 1997 ident: 3843_CR11 publication-title: Arthritis Rheum doi: 10.1002/art.1780400928 – volume: 78 start-page: 1151 issue: 9 year: 2019 ident: 3843_CR13 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-214819 – volume: 43 start-page: 77 issue: 1 year: 2013 ident: 3843_CR39 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2012.12.002 – volume: 145 start-page: 61 issue: 1 year: 2022 ident: 3843_CR53 publication-title: Circulation – volume: 62 start-page: 881 issue: 6 year: 2010 ident: 3843_CR45 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.20122 |
| SSID | ssj0025774 |
| Score | 2.4521358 |
| Snippet | Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed... Background Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective... In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry. aPLs profile, including anticardiolipin... BackgroundPatients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study,... Abstract Background Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 8 |
| SubjectTerms | Adult Antibodies Antibodies, Antiphospholipid - blood Anticoagulants Antiphospholipid antibodies Antiphospholipid antibodies (aPLs) Antiphospholipid syndrome (APS) Arteriosclerosis Arthritis Aspirin Asymptomatic Atherosclerosis Atherosclerosis - blood Atherosclerosis - complications Atherosclerosis - epidemiology Atherosclerosis - immunology Atherosclerotic cardiovascular disease (ASCVD) Autoimmune diseases Body mass index Cardiolipin Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - immunology Care and treatment Cerebral infarction China - epidemiology Chronic conditions Confounding (Statistics) Diabetes Diagnosis Female Glycoprotein I Glycoproteins Health risks Heart attacks Humans Hyperlipidemia Hypertension Immunoglobulin G Immunoglobulin Isotypes - blood Immunoglobulin M Isotypes Lupus Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - epidemiology Lupus Erythematosus, Systemic - immunology Male Medical imaging Medical prognosis Middle Aged Myocardial infarction Patients Prevention Prospective Studies Quality control Regression analysis Review boards Risk Factors Systemic lupus erythematosus Systemic lupus erythematosus (SLE) Testing Thrombosis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJssCxgJCRCKto4fcbiVFdUWaTlAQb1Zju1oI1VJ1bSH_T380Z1x0qoRElw45JD4i5R4JvOIx98Q8lZqC1mXlalltkpFLm2qhQRjyCuVucJ7HovHr76py5_i61Iuj1p9YU1YTw_cT9x5wa22ECeXWZDCVcqynKtKSyUm2ksd0PqCz9snU0OqJSGq2W-R0eq8A6_GsNhWpBOucb155IYiW_-fNvnIKY0LJo880OwBuT-EjnTaP_JDcic0j8jdq2Fx_DH5PYv8IDTGdG0HmE0LUOpGJad0WJKhdUN7GmeArHbrXUfD5qbncG07OEP_5mnb0Isfi-l3-n65_DWfzz98ooChfRkIbSu677CypSCjen3ddnCs6nXt44WyxTJFWnct_uztnpDF7Mvi4jIdejCkThZym5bMBa6K0gbIlWXmKjsppRdu4qRXhag8hDg5DPkyc0FkWcWkZcJal4VgeeBPyUnTNuE5oVrmVVVYxsvcCmSNC95DLua4zDNR6klC2F4ixg385NgmY2VinqKV6aVoQIomStEUCfl4uGfds3P8Ff0ZBX1AIrN2vAD6ZgZ9M__St4S8RjUx_TbVg30wUyzHFRwiqIS8iwi0EPACzg4bHWAakGtrhDwbIeHLduPhvSqawbJ0hjPsCQ9xYJ6QN4dhvBOr5ZrQ7iKGgZdTTCXkWa-5h5eG-FNCCs8Sokc6PZqV8UhTX0fecWxShDunT__HPL4g9zJspYx_s9QZOdluduElxHfb8lX8lG8By0xNrA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxHsDCxgJCRCKto4fcbigsqLaIi0HWFBvkWM7bKQqLk174PfwR5lx0u5GSHvoIfEXqcmM52GPvyHktdQGsi4jU8NMnYpcmlQLCcaQ1yqzhXM8Fo-ffVWnP8SXhVwMC27dUFa5s4nRULtgcY38mDPshQ3-L_-4-p1i1yjcXR1aaNwkt5C6DLU6X1wmXBJim91BGa2OO_BtDEtuRTrhGnedR84ocvb_b5mvuKZx2eQVPzS7R-4OASSd9hK_T2749gG5fTZskT8kf2eRJYTGyC50gFkHgFI7Kjylw8YMbVrakzkDZLldbTvq1396JtfQwRV6OUdDS0--n0-_0beLxc_5fP7uAwUM7YtBaKjprs_KhoKkmtVF6OC3bFaNizeqgMWKtOkCLvl2j8j57PP5yWk6dGJIrSzkJq2Y9VwVlfGQMcvM1mZSSSfsxEqnClE7CHRyGHJVZr3IsppJw4QxNvPecM8fk4M2tP6QUC3zui4M41VuBHLHeecgI7Nc5pmo9CQhbCeR0g4s5dgsY1nGbEWrspdiCVIsoxTLIiHv98-seo6Oa9GfUNB7JPJrxxth_ascpmtZcKMNZGdV5qWwtTIs56rWUomJdlL7hLxENSn7w6p7K1FOsShXcIijEvImItBOwAtYMxx3gM-AjFsj5NEICfPbjod3qlgO9qUrL2dDQl7th_FJrJlrfdhGDANfp5hKyJNec_cvDVGohESeJUSPdHr0VcYjbXMR2cexVRGen356_f96Ru5k2CoZV6vUETnYrLf-OcRvm-pFnKT_AFvzRdA priority: 102 providerName: ProQuest |
| Title | Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39757171 https://www.proquest.com/docview/3152697417 https://www.proquest.com/docview/3151876616 https://pubmed.ncbi.nlm.nih.gov/PMC11702278 https://doaj.org/article/93a8a230b2e54cf6a1736f856408d58e |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_3Ace9iN9WzzWCoCLVTZO0qSCye9xyK-wh650s9xLSNPUKS7tud8H7e_xHnaQfXPHwwYcW2kwekpnJzCST3yD0igsFUZfiviIq81nElS8Yh8WQZmGg4zSlLnl8dhaeXrAvC77YQW25o2YCq1tDO1tP6mK9fP_r5_VnUPhPTuFF-KECm0VsKi3zh1TY0-RdtA-WKbIVDWasO1UA6YxYe3Hm1n6H6ADsM4cQh_TslIPz_3vRvmG1-hmVN0zU5C660_iWeFQLwz20Y4r76GDWnJ4_QL8nDkAEO6evrIBmXQIp1r2cVNyc2eC8wDXOM5Ast6tthc36ugZ5LSv4sgYwxWWBj7-dj-b4zWLxfTqdvv2IgQbXeSK4zHBbgmWDgYn56qqs4Fnmqzx1P5LS5jHivCrtbnD1EJ1PTs6PT_2mSIOvecw3fkK0oWGcKAPBNA90poYJT5keap6GMctS8IEiaEqTQBsWBBnhijCldGCMooY-QntFWZgnCAseZVmsCE0ixSysnElTCNY05VHAEjH0EGk5InUDYG7raCylC2REKGuGSmCodAyVsYfedX1WNXzHP6nHltEdpYXedj_K9Q_ZaLKMqRIKArckMJzpLFQkomEmeMiGIuXCeOiFFRNZ32PtFhA5svm6jIKL5aHXjsIKNQxAq-YmBEyDBePqUR71KEH1db-5FUXZao6kxBaNB0cx8tDLrtn2tOl0hSm3joaAGQxJ6KHHteR2g24VwEOiJ9O9Wem3FPmVAya3VYzs1eqn_9_1GToMbIVlt8l1hPY26615Dm7fJhmg3WgRDdD--OTs63zgNk8GTr_hPR9f_gGwhFr_ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWRQIuiDeBhTUSCBCKNk7sPJAQKgtVyz4O0EW9WY7tsJWqpDSt0P4ezvxHZpykuxHS3vaQQ-MvUZOZzDdjj2cIeSlSBVGXEr5iqvB5IpSfcgHGMCriUGfGRC55_Og4Hp3wr1Mx3SJ_u70wmFbZ2URnqE2lcY58L2LYCxv4L_m4-OVj1yhcXe1aaDRqcWDPfkPIVn8Yfwb5vgrD4ZfJ_shvuwr4WmRi5edM2yjOcmUh-hOhLlSQC8N1oIWJM14YIO0EhkweasvDsGBCMa6UDq1VkY3gttfIdeDdAGO9ZHoe3wlwpbp9OWm8VwOVMszw5X4QpbjI3eM-1yLgfyK4wIT9LM0LtDe8Q263_iodNAp2l2zZ8h65cdSuyN8nf4auKAl1jmRVA2ZZAZTqXp4rbdeB6KykTe1ogMzXi3VN7fKsKRxb1fALSdXQqqT73yeDb_TNdPpjPB6_fU8BQ5vcE1oVtGvrsqKgGLPFaVXDMZ8tZsadyCvMjaSzusIZ5voBmVyFiB6S7bIq7WNCU5EURaZYlCeKY6k6awwEgDoSScjzNPAI6yQidVsUHXtzzKULjtJYNlKUIEXppCgzj7zbXLNoSoJciv6Egt4gsZy3O1Etf8rWOsgsUqmCYDAPreC6iBVLorhIRcyD1IjUemQX1UQ2e2M3RkkOMAeYR-C2eeS1Q6BZggfQqt1dAa8BC3z1kDs9JJgT3R_uVFG25qyW5x-fR15shvFKTNErbbV2GAbUGrPYI48azd08NDi9ImEJ80ja0-neW-mPlLNTV-wcOyPhdu0nl_-vXXJzNDk6lIfj44On5FaIXZpxoizeIdur5do-A9dxlT93Hywl8ooNxD_QXoPX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Future+atherosclerotic+cardiovascular+disease+in+systemic+lupus+erythematosus+based+on+CSTAR+%28XXVIII%29%3A+the+effect+of+different+antiphospholipid+antibodies+isotypes&rft.jtitle=BMC+medicine&rft.au=Huang%2C+Can&rft.au=Ding%2C+Yufang&rft.au=Chen%2C+Zhen&rft.au=Wu%2C+Lijun&rft.date=2025-01-06&rft.pub=BioMed+Central&rft.eissn=1741-7015&rft.volume=23&rft_id=info:doi/10.1186%2Fs12916-024-03843-9&rft_id=info%3Apmid%2F39757171&rft.externalDocID=PMC11702278 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |